The NIH has created the NIH StrokeNet to conduct small and large clinical trials and research studies to advance acute stroke treatment, stroke prevention, and recovery and rehabilitation following a stroke. This network of 25 regional centers across the U.S., which involves more than 200 hospitals, is designed to serve as the infrastructure and pipeline for exciting new potential treatments for patients with stroke and those at risk for stroke. In addition, NIH StrokeNet will provide an educational platform for stroke physicians and clinical trial coordinators.
The Institute for Stroke and Cerebrovascular Diseases is The Gulf Regional Area Stroke Programs and Oklahoma (GRASP-OK) Consortium a collaborative research effort between sites located in Texas, Oklahoma, Louisiana, Alabama, and Mississippi and intends to serve the needs of an incredibly diverse population of patients throughout the Gulf states. GRASP conducts high quality clinical research devoted to identifying new treatments in stroke prevention, acute stroke management, and stroke recovery. We are currently enrolling in the following StrokeNet trials:
STUDY OF DEFEROXAMINE MESYLATE IN INTRACEREBRAL HEMORRHAGE (iDEF): The focus of this study is to evaluate the investigational drug, deferoxamine mesylate or deferoxamine. This drug removes iron. Blood in the brain after a brain hemorrhage contains iron and this iron damages the brain. We are studying whether removal of iron from the brain hemorrhage will reduce the effects of the brain hemorrhage. We will look specifically at a person’s ability to function well and to think well after a brain hemorrhage. We will also learn more about the safety of the investigational drug.
CAROTID REVASCULARIZATION AND MEDICAL MANAGEMENT FOR ASYMPTOMATIC CAROTID STENOSIS TRIAL (CREST-2): Prevention of stroke involves managing and treating risk factors. Most strokes are caused when blood flow to a portion of the brain is blocked. One place this often happens is in the carotid artery. This blockage is called atherosclerosis or hardening of the arteries. The purpose of this trial is to determine the best way to prevent strokes in people who have a high amount of blockage of their carotid artery but no stroke symptoms related to that blockage. Each eligible participant will be evaluated to determine which procedure(s) is best for him/her. All participants will receive intensive medical treatment. In addition, participants will be randomized to receive the selected procedure or not.
ATRIAL CARDIOPATHY AND ANTITHROMBOTIC DRUGS IN PREVENTION AFTER CRYPTOGENIC STROKE (ARCADIA): A randomized trial of apixaban versus aspirin specifically in patients with cryptogenic stroke who have evidence of atrial cardiopathy. This trial will address several important knowledge gaps. First, it will advance our understanding of stroke pathophysiology by assessing whether atrial cardiopathy is a valid therapeutic target, which may set the stage for a primary prevention trial. Second, this trial will advance our understanding of optimal secondary stroke prevention therapy.
Should you have an interest in learning more our The Institute for Stroke and Cerebrovascular Disease’s involvement in StrokeNet contact:
Chad Tremont, BS